Drugs and foods on contraction of endothelial cells as a key mechanism in atherogenesis and treatment of atherosclerosis with endothelial-cell relaxants (cyclic AMP phosphodiesterase inhibitors).
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000818:Animals; D001011:Aorta / Q000473:pathology / Q000502:physiology; D001158:Arteries / Q000187:drug effects / Q000502:physiology; D001161:Arteriosclerosis / Q000209:etiology / Q000628:therapy; D001692:Biological Transport / Q000187:drug effects; D001777:Blood Coagulation / Q000187:drug effects; D001792:Blood Platelets / Q000502:physiology; D002914:Chylomicrons / Q000378:metabolism; D004727:Endothelium / Q000187:drug effects / Q000502:physiology; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D008075:Lipoproteins, HDL / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000378:metabolism; D008079:Lipoproteins, VLDL / Q000378:metabolism; D010726:Phosphodiesterase Inhibitors; D010974:Platelet Aggregation; D011727:Pyridinolcarbamate / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D002914:Chylomicrons; D004791:Enzyme Inhibitors; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D010726:Phosphodiesterase Inhibitors; D011727:Pyridinolcarbamate; D015105:3',5'-Cyclic-AMP Phosphodiesterases